Total medical devices industry venture financing deals worth $1.2bn were announced in the US in November 2021, led by $180m venture financing of Owkin, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked a decrease of 36.7% over the previous month of $1.91bn and a drop of 11.03% when compared with the last 12-month average of $1.36bn.
The US held a 56.02% share of the global medical devices industry venture financing deal value that totalled $2.16bn in November 2021.
In terms of venture financing deal activity, the US recorded 52 deals during November 2021, marking an increase of 1.96% over the previous month and a drop of 22.39% over the 12-month average.
US medical devices industry venture financing deals in November 2021: Top deals
The top five medical devices industry venture financing deals accounted for 52.8% of the overall value during November 2021.
The combined value of the top five medical devices venture financing deals stood at $640m, against the overall value of $1.2bn recorded for the month.
The top five medical devices industry venture financing deals of November 2021 tracked by GlobalData were:
1) Sanofi $180m venture financing deal with Owkin
2) The $130m venture financing of Luma Health by FTV Capital
3) Atlas Venture,Casdin Capital,Cormorant Asset Management,Janus Henderson Investors,Newpath Management,Omega Fund Management,Sofinnova Partners,T Rowe Price Associates and Wellington ManagementLLP $125m venture financing deal with Chroma Medicine
4) The $105m venture financing of Geneoscopy by BioGenerator,Cultivation Capital,Innovatus Capital Partners,Laboratoryof America Holdings,Lightchain,Morningside Ventures and NT Investments
5) Emerson Collective,General Catalyst Partners,Kindred Ventures,T Rowe Price Associates and Viking Global Investors $100m venture financing deal with Color Health
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.